Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3315576,plasma half-life,Anisoylated plasminogen streptokinase activator complex (APSAC) is a recently developed thrombolytic agent with high fibrin-binding potential and sustained release pharmacokinetics (plasma half-life 70 minutes).,Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315576/),min,70,63629,DB00029,Anistreplase
,2049230,volumes of distribution,"2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).",A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049230/),l,5.68,68177,DB00029,Anistreplase
,2049230,volumes of distribution,"2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).",A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049230/),l,5.90,68178,DB00029,Anistreplase
,2049230,terminal phase half-life,"2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).",A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049230/),h,0.61,68179,DB00029,Anistreplase
,2049230,terminal phase half-life,"2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).",A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049230/),h,1.16,68180,DB00029,Anistreplase
,2049230,mean residence time,"2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).",A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049230/),h,0.76,68181,DB00029,Anistreplase
,2049230,mean residence time,"2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).",A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049230/),h,1.55,68182,DB00029,Anistreplase
,1372625,steady state plasma concentrations,"Mean steady state plasma concentrations of alteplase during the initial 30 min were 3.2 +/- 0.84 micrograms/ml, measured immunochemically, and 2.1 +/- 0.23 micrograms/ml, measured using a functional activity assay.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],3.2,137822,DB00029,Anistreplase
,1372625,steady state plasma concentrations,"Mean steady state plasma concentrations of alteplase during the initial 30 min were 3.2 +/- 0.84 micrograms/ml, measured immunochemically, and 2.1 +/- 0.23 micrograms/ml, measured using a functional activity assay.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],2.1,137823,DB00029,Anistreplase
,1372625,plasma half-life,"However, the predominant plasma half-life determined by model fitting based on either assay (3.3 to 3.5 min) was unaltered compared with the standard regimen.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),min,3.3 to 3.5,137824,DB00029,Anistreplase
,1372625,Maximal concentrations,"Maximal concentrations of fibrin and fibrinogen degradation products were 5.1 +/- 2.2 and 1.9 +/- 1.1 micrograms/ml, respectively.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],5.1,137825,DB00029,Anistreplase
,1372625,Maximal concentrations,"Maximal concentrations of fibrin and fibrinogen degradation products were 5.1 +/- 2.2 and 1.9 +/- 1.1 micrograms/ml, respectively.",Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1372625/),[μg] / [ml],1.9,137826,DB00029,Anistreplase
,3887635,deacylation half-life,"These were BRL 26921 (deacylation half-life, 40 min) and BRL 33575 (deacylation half-life c. 17 hr).",Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887635/),min,40,143664,DB00029,Anistreplase
,3887635,deacylation half-life,"These were BRL 26921 (deacylation half-life, 40 min) and BRL 33575 (deacylation half-life c. 17 hr).",Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887635/),h,c.,143665,DB00029,Anistreplase
,3887635,deacylation half-life,"These were BRL 26921 (deacylation half-life, 40 min) and BRL 33575 (deacylation half-life c. 17 hr).",Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887635/),h,17,143666,DB00029,Anistreplase
,3887635,clearance half-life,The pharmacokinetic clearance rate of BRL 33575 from the circulation was studied and gave a clearance half-life of about 7 hr.,Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3887635/),h,7,143667,DB00029,Anistreplase
,2653017,activity half-lives,"After SK, activator activity half-lives were 184 minutes (group B) and 169 minutes (group C), and after APSAC 188 minutes (group D).","Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653017/),min,184,155238,DB00029,Anistreplase
,2653017,activity half-lives,"After SK, activator activity half-lives were 184 minutes (group B) and 169 minutes (group C), and after APSAC 188 minutes (group D).","Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653017/),min,169,155239,DB00029,Anistreplase
,2653017,activity half-lives,"After SK, activator activity half-lives were 184 minutes (group B) and 169 minutes (group C), and after APSAC 188 minutes (group D).","Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653017/),min,188,155240,DB00029,Anistreplase
,3514485,clearance half-life of fibrinolytic activity,A pharmacokinetic study was performed in six patients demonstrating a clearance half-life of fibrinolytic activity of 87.5 +/- 5.0 min.,Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514485/),min,87.5,261254,DB00029,Anistreplase
